News & Updates

Psychosis: Has perceived public stigma changed in Hong Kong?
Psychosis: Has perceived public stigma changed in Hong Kong?
04 Nov 2022

Perceived public stigma (PPS) towards psychosis has remained static over 9 years in Hong Kong, with different education groups showing unique patterns of changes in PPS and endorsement of medication treatment across the years, researchers from the University of Hong Kong (HKU) have reported.

Psychosis: Has perceived public stigma changed in Hong Kong?
04 Nov 2022
Vebicorvir plus entecavir safe, effective in chronic HBV patients
Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022 byStephen Padilla

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.

Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022
Serum cholesterol efflux capacity underpins early AMD
Serum cholesterol efflux capacity underpins early AMD
03 Nov 2022 byTristan Manalac

Patients with early age-related macular degeneration (eAMD) appear to have increased serum cholesterol efflux capacity, according to a recent Singapore study. The same is true for polypoidal choroidal vasculopathy (PCV), but not for typical neovascular AMD (tAMD).

Serum cholesterol efflux capacity underpins early AMD
03 Nov 2022
Extended-release nifedipine benefits women with severe pre-eclampsia
Extended-release nifedipine benefits women with severe pre-eclampsia
02 Nov 2022